Regeneron's Dupixent Passes the FDA Muster; Baird Sees Strong Lauch
March 28, 2017 at 12:41 PM EDT
Atopic dermatitis treatment candidate Dupixent jointly developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|